NTCELL reverses the progression of Parkinsons disease
Filed with ASX · · 4 pages · English
Algorae Pharmaceuticals Limited on 6ix
Later from Algorae Pharmaceuticals
- LCT receives ethics approval for Phase IIb Parkinsons trial
- LCT completes $2.8m private placement and announces SPP
- LCT starts Phase IIb clinical trial of NTCELL
- LCT JV secures funds to realise the potential of DIABECELL
- NTCELL demonstrates continued reversal of Parkinsons
Follow Algorae Pharmaceuticals into a list and get an email when it puts out news.
Follow Algorae Pharmaceuticals